BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

InKine Pharmaceutical Company, Inc. (INKP) Earns Milestone Payment As Zeria Pharmaceutical Co., Ltd. Advances Development Of Tablet Purgative -Visicol- For Sale In Japan


10/19/2005 5:13:09 PM

BLUE BELL, Pa.--(BUSINESS WIRE)--March 29, 2005--InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that it has earned a $1.0 million milestone payment from Zeria Pharmaceutical Company, LTD., InKine's licensee for sodium phosphate tablets for use as a colonic purgative, bowel cleansing agent or laxative for sale in Japan. Under the terms of the license agreement, $1.0 million was payable to the Company upon the submission of a new drug application to Japan's Ministry of Health, Labor, and Welfare (MHLW) for the licensed product. An additional milestone will be payable to InKine under the license upon the MHLW approval of a new drug application for the licensed product. Under the terms of the Company's license, the ALW Partnership, the owners of the Visicol(R) patent, shall receive a royalty from InKine in the amount of $300,000 as a result of the Zeria milestone payment. "Development milestone payments such as these represent the continuing realization of our global strategy to create collaborations to fully maximize the value of Visicol(R)," said Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executive Officer of InKine. "We are delighted to work with our collaborators to effectively deliver our products to patients around the world," added Dr. Jacob.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->